On July 26, 2022, Zhejiang Hengkang Pharmaceutical Co., Ltd. and Walvax Biotechnology Co., Ltd. held the signing ceremony of strategic cooperation, opened the mileage of strategic cooperation between our company and Walvax, and established closer technical cooperation between the two sides in the development of new products in Vaccine!
Walvax, as a high-tech vaccine producer with a historical sense of responsibility, is the benchmark of the Chinese vaccine industry. In 2010, Walvax was successfully listed on the Shenzhen Stock Exchange (stock code: 300142) and became the first company in Yunnan Province to list on China GEM. Walvax has always insisted on fulfilling the theme of "making people live and healthy", integrating social responsibility into the company's development strategy and business management, taking strict compliance with product quality and safety as its responsibility, not forgetting the initial heart, closely following the footsteps of the times, and striving to create outstanding achievements worthy of society and the times.
The signing of the strategic agreement is exciting; this is the beginning of a milestone for both sides, and Zhejiang Hengkang Pharmaceutical is honored to become Walvax's strategic partner!
Zhejiang Hengkang Pharmaceutical Co., Ltd., is a pharmaceutical company covering the research and development of pharmaceutical materials to large-scale production to global marketing. The company has been committed to the research and development, production and sales of APIs, intermediates, committed to providing customers with high-quality pharmaceutical products and professional services; the company has plants and facilities in line with cGMP standards, professional GMP and EHS management system and marketing team. Our business is throughout China, Europe, Japan and South Korea, CIS region, the Middle East and other mainstream pharmaceutical markets and emerging pharmaceutical markets; after many years of team efforts, it has established long-term and stable cooperation relations with nearly 70+ overseas countries and hundreds of Chinese enterprises. The company has obtained domestic and foreign registration certificates for many products, and has passed on-site inspections by official institutions such as NMPA in China, EDQM in the European Union, PMDA in Japan, and KFDA in South Korea for many times. The company has a number of core patents for independent research and development products, and has successively won the honor of national high-tech enterprises, provincial research institutes and so on.
The nucleic acid business segment of the Group focuses on the independent research and development and production of key raw materials and excipients, nucleotides, modified nucleotides, cap analogues, cationic liposomes, phosphoramidits, etc. of mRNA and Oligonucleotides. The Company has many years of industrialization experience, builds a large production base with advanced GMP system, 8 billion doses of production capacity, ensures the stable supply of high-quality raw materials, solves key cost problems and neck engineering, and improves the industrial pattern; we go all out to do a good job in supply chain services.
The signing of this strategic agreement will help the R & D and marketing of Walvax nucleic acid vaccine. Our company will become the best partner of Walvax nucleic acid raw materials, build a moat, jointly create competitiveness, closely follow the footsteps of the times, and make due contributions to the vaccine cause of the Chinese people and the cause of human health!
